- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04542239
Inclined Positioning and Infant Gastroesophageal Reflux (Infant GER)
Inclined Positioning and Infant Gastroesophageal Reflux Indicators
Study Overview
Status
Conditions
Detailed Description
Mothers will bring their infants to the Clinical Research Center where they will be escorted to a private room. Participants will proceed to feed their infant a typical liquid meal (i.e. breastmilk or formula). Within 15 minutes of completion of the feed, infants will be placed in the prototype infant reclining device at either 0, 10, 18, or 28 degrees of incline. Infants will spend 15 minutes at each level of incline in a randomly assigned order. During this time period that each infant is under observation the infant may be entertained/distracted/comforted with white noise, music or other forms of distraction as determined by the mother or study team. Mothers may touch/caress their infant or use a pacifier to soothe infant as needed so long as each 15 minute segment is completed. Following each 15 minute segment, a "washout" period will be used such that the next 15 minute segment will not begin for a minimum of 1 minute to a maximum of 5 minutes in duration before the next incline position is begun. This allows for a clean start and stop period for each 15 minute segment that is not impacted by either the prior position or the change to the new position. This also allows mothers or study staff to pick up and comfort the infant.
During each of the four 15 minute segments, infants will be monitored using the Masimo RAD-97 pulse oximeter with data continuously collected regarding oxygen saturation and heart rate in 2-second intervals. The oxygen saturation probe will preferably be attached to a big toe, but can be placed in alternative spots consistent with usual clinical care such that a consistent reading of heart rate and oxygen saturation are recorded. A study coordinator will complete a data collection form for each segment characterizing whether GER occurred (spit-up into mouth or outside of mouth), the number of GER episodes as well as a subjective assessment of degree crying/fussing, hiccups, back arching, and breathing difficulty. The coordinator will also have a timer to measure the duration of crying in each position. Infants will be video recorded as a backup method for symptom assessment and for qualitative assessments by the study sponsor.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- born at >= 34 weeks gestation
- weight for age >= 10th percentile
- No serious medical conditions
- English-speaking parent capable of consenting
- Diagnosis of GER from healthcare provider (not necessary for controls)
- 4 or more visible spit-ups (mouth or nose) per day for at least 5 days OR 2 or more spit-ups out of the nose per day for at least 5 days OR I-GERQ score >=16 (not necessary for controls)
- If applicable, parent willing to refrain from giving medication for GER for 12 hours prior to study participation
Exclusion Criteria:
- Signs of a more serious or complex illness including weight loss, lethargy, fever, excessive irritability/pain, bulging fontanelle, seizures, macro/microcephaly, bilious vomiting, hematemesis, chronic diarrhea, rectal bleeding, suspicions of GI obstruction
- History of a Brief Resolved Unexplained Event (BRUE)
- Use of a Home Apnea Monitor prescribed by a healthcare provider
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
Infants with GER
Infants (N=25) meeting inclusion/exclusion criteria
|
Controls without GER
Infants (N=10) meeting inclusion/exclusion criteria, but no GER
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of hypoxic episodes
Time Frame: 1 hour observation period
|
Evaluate the extent to which infants exhibit oxygen desaturation (oxygen saturation <94%) in each position
|
1 hour observation period
|
Number of bradycardia episodes
Time Frame: 1 hour observation period
|
Evaluate the extent to which infants exhibit bradycardia (heart rate <100 beats per minute) in each position
|
1 hour observation period
|
Number of observed regurgitations
Time Frame: 1 hour observation periods
|
Evaluate the extent to which infants exhibit clinical signs and symptoms of post-feed regurgitation in each position
|
1 hour observation periods
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time spent in hypoxic episodes
Time Frame: 1 hour observation period
|
Minutes spent in hypoxia in each position
|
1 hour observation period
|
Time spent in bradycardic episodes
Time Frame: 1 hour observation period
|
Minutes spent in bradycardia in each position
|
1 hour observation period
|
Time spent fussing or crying
Time Frame: 1 hour observation period
|
Minutes spent fussing or crying in each position
|
1 hour observation period
|
Observed cyanosis episodes
Time Frame: 1 hour observation period
|
Number of episodes of observed cyanosis (turning blue) in each position
|
1 hour observation period
|
Subjective assessment of crying, hiccups, back arching, and respiratory distress
Time Frame: 1 hour observation period
|
Yes/no answer in each position
|
1 hour observation period
|
Subjective maternal perception of infant comfort in each position
Time Frame: 1 hour observation period
|
very comfortable, comfortable, neither comfortable nor uncomfortable, uncomfortable, very uncomfortable
|
1 hour observation period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ian M Paul, MD, Penn State College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRP591
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
King Chulalongkorn Memorial HospitalCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States